Modulating ApoE Signalling to Reduce Brain Inflammation, deLirium and postopErative Cognitive Dysfunction
Status:
Recruiting
Trial end date:
2022-12-17
Target enrollment:
Participant gender:
Summary
This research study will evaluate the effectiveness and estimate the feasibility of
administering an investigational drug called 'CN-105' (the study drug), to prevent
postoperative cognitive decline, delirium (serious confusion) and underlying brain
inflammatory and brain activity changes in adults 60 years and older undergoing surgery.